Clinical trials: Alcohol Liver Disease
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Alcoholic Liver Disease
Gut Mycobiome Profile in Alcoholic Liver Disease.
The fecal mycobiome, which refers to the community of fungi that resides in the human gut, is an important component of the gut microbiome.
- Trial name
- NCT05793190
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Alcoholic Hepatitis, Acute Liver Failure
Outcomes Using MARS for Patients With ALF
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival…
- Trial name
- NCT05594953
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Methodist Health System
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Alcoholic Hepatitis
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Drinking large amount of alcohol can cause damage to the liver. If the liver is severely injured by alcohol it can become very inflamed and this condition is called alcoholic hepatitis.
- Trial name
- CREED (NCT04544020)
- Testing
- NG feeding
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Aberdeen
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Alcohol-Related Disorders
AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease
Alcohol contributes to over 5% of deaths worldwide, and death rates from alcohol-related liver disease (ARLD) in the UK continue to rise sharply.
- Trial name
- NCT03474328
- Testing
- AlcoChange
- Volunteers
- 60 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
HIV, Metabolic Syndrome
Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho
This study is conducted in a cohort of HIV-positive patients on first-line anti-retroviral therapy (ART) in rural health facilities in Lesotho, Southern Africa.
- Conditions
- HIV, Metabolic Syndrome, Depression, Alcoholism
- Trial name
- NCT02126696
- Where
- 2 sites in Lesotho
- Volunteers
- 1,754 people
- Sponsor
- Swiss Tropical & Public Health Institute
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Hepatocellular Carcinoma
Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma
Assessment of the long-term outcome of combined ipsilateral liver lobe devascularization (ILAD) and alcohol injection of the large hepatocellular carcinoma (HCC): single center non-randomized trial.
- Trial name
- NCT03138044
- Testing
- Combined Treatment
- Where
- Sudan
- Volunteers
- 12 people
- Sponsor
- The National Ribat University
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Carcinoma, Hepatocellular, Alcoholic Cirrhosis
Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
The aim of the investigators' study is to elucidate the relationship between a functional liver test (e.g., ICG) and the PREOPERATIVE value of portal hypertension in the patients with impaired liver function from alcoholic and…
- Conditions
- Carcinoma, Hepatocellular, Alcoholic Cirrhosis, Viral Cirrhosis, Postoperative Hepatic Failure
- Trial name
- NCT00827723
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Lausanne Hospitals
Lysosomal Acid Lipase Deficiency
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
- Trial name
- NCT02193867
- Testing
- Sebelipase Alfa
- Where
- 5 sites in United States, Finland and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Failure, Hepatitis B
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
This study evaluates the Granulocyte colony-stimulating factor (G-CSF) in the treatment of Acute on Chronic Liver Failure in adult.
- Conditions
- Liver Failure, Hepatitis B, Alcoholic Liver Disease
- Trial name
- NCT02331745
- Testing
- Granulocyte colony-stimulating factor, standard treatment
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing 302 Hospital